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Aplastic anemia (AA) is a potentially lifelthreatlening failure of hematopoiesis characterized by pancytopenia and bone marrow aplasia.1 
Patients with aplastic anemia have a stem cell defect 
both in proliferation and differentiation as shown by 
longlterm bone marrow culture, longlterm cell assays 
and committed progenitor assays.2 Patients with AA 
have an increased risk of developing clonal hematologil
cal diseases including paroxysmal nocturnal hemoglol
binuria (PNH), myelodysplastic syndrome (MDS) or 
acute myeloid leukemia (AML).3,4 The evolution from 
AA to MDS/AML is marked with increased proliferal
tive activity with or without development of cytogenetic 
abnormalities. Around 10% to 20% of survivors of AA 
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prognosis and therapeutic response in patients 
with aplastic anemia
develop a clonal hematological disease within the decade 
following immunosuppressive therapy.4,5 It is uncertain 
whether the development of secondary MDS or acute 
leukemia simply discloses the natural history of AA as 
a premalignant disease or whether it is related to the 
therapy applied.5 There is a possibility that a proportion 
of cases of AA may be in fact cases with preleukemia.6
Cellular proliferation is an important prognostic 
parameter in cancers. Failure of proliferation, in the hel
matopoietic stem cells of AA patients is well known, 
whereas there is proliferation but with abnormal and 
minimal or no differentiation in cases of MDS/AML. 
The measurement of dividing cell fraction in Slphase 
by means of flow cytometry is an established method 
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for assessing proliferative activity. Histograms obtained 
by flow cytometry provide information related to neol
plastic progression, i.e. SPF and ploidy. SPF measures 
the percentage of a given cycling subpopulation between 
G0/G1 and G2/M phase and represents a continuous 
variable related to any proliferating cell population.7 SPF 
status has been studied in different hematological disorl
ders including MDS, chronic myeloid leukemia, acute 
lymphoblastic leukemia, nonlHodgkin lymphomas and 
solid tumors such as prostate cancer and breast cancer 
for the purpose of prognostic classification.7l14
Determining the prognosis of patients with AA 
requires a careful assessment of conventional clinicol
pathologic parameters including dysplastic changes in 
peripheral blood, percentage of blasts in bone marrow 
and cytogenetic abnormalities.15l18 However, these conl
ventional factors have limited value in predicting the 
prognosis in individual patients; additional parameters 
are needed to achieve this goal. Reliable biomarkers are 
still lacking, and therefore, the clinical outcome is diffil
cult to predict. The aim of the present work was to anal
lyze the proliferation rate of peripheral blood cells using 
a standard and reproducible method (i.e., flow cytoml
etry) to measure SPF to explore the relationship with 
disease characteristics and the value of SPF in predicting 
prognosis. We also investigated whether the SPF value 
influenced the response to immunosuppressive therapy 
in patients with AA.
PATIenTS AnD MeThODS
The study group comprised of 53 consecutive patients 
with AA and 30 agel and sexlmatched healthy subjects. 
The diagnosis of AA was made on the basis of complete 
blood count (CBC), bone marrow aspiration, and bil
opsy. The severity of AA was defined according to stanl
dard criteria. Patients who had received antillymphocyte 
globulin/antilthymocyte globulin, steroids or other iml
munosuppressive therapy were excluded from the study. 
All AA patients were given cyclosporine (5l10 mg/kg/
day) as no patient was able to afford ATG/ALG or bone 
marrow transplantation (BMT). The patients were foll
lowedlup periodically for the response to treatment and 
side effects to the medication. The dosage of cyclospol
rine was adjusted according to clinicolhematological pal
rameters. Investigations were performed at the time of 
diagnosis and prior to treatment. The SPF analysis and 
bone marrow examinations (aspiration and biopsy) were 
done at 6lmonth intervals whereas cytogenetic analysis 
was performed yearly. All patients with AA were also 
evaluated for the presence of PNH using the flow cyl
tometry and sucrose lysis test at diagnosis and during 
follow up. Informed written consent was obtained from 
patients and control subjects. The study protocol was 
approved by the institutional ethics committee.
Flow cytometric analysis. SPF analysis (cell cycle anall
ysis) was carried out according to the Krishnan methl
od.19 Peripheral blood was collected in a sodium heparin 
Vacutainer vial and 100 µL of heparinized peripheral vel
nous blood was added to 1 mL of propidium iodide sol
lution (50 µg/mL in 0.1% hypotonic solution of sodium 
citrate) and incubated for 10 min at 40°C. A 10 minute 
staining time at 40°C proved to provide the best histol
gram resolution. Samples were analyzed on a Becton 
Dickinson flow cytometer with Mod FitlLT V 3.0 softl
ware using an excitation wavelength of 488 mm. Cells 
acquired on flow cytometry were plotted in sidelscatl
tered light versus forwardlscattered light, fluorescencel2 
area (FLl2A) versus fluorescencel2 width (FLl2W) and 
FLl2A versus count. The threshold was adjusted to have 
a first peak at the 200 channel of the FLl2W plot and 
the lymphocyte cell population was gated from a plot of 
FLl2A versus FLl2W for analysis. Gated lymphocytes 
were analyzed using a broadened rectangular model of 
Mod FITlLT software with a constant coefficient of 
variation <6 and a residual chilsquare <5. This model 
was also fitted with singlelcut debris subtraction and 
aggregate subtraction. Ten thousand cells were analyzed 
per sample. Human peripheral blood lymphocytes from 
hematologically normal subjects were used as a diploid 
reference standard. 
Response criteria. Complete response was defined as 
transfusion independence associated with hemoglobin 
(Hb) >11 g/dL, an absolute neutrophil count (ANC) 
>1.5×109/L and a platelet count >100×109/L. Partial 
response was defined as transfusion independence asl
sociated with Hb >8 g/dL, ANC >0.5×109/L and a 
platelet count >30×109/L. Transfusion dependence was 
taken as evidence of no response.20
Statistical analysis. The findings were expressed as the 
mean and standard deviation. The differences between 
the groups were compared with the use of the t test. The 
chilsquare test was used when appropriate. A value of 
P≤.05 was considered statistically significant.
ReSULTS
Fiftylthree consecutive patients with AA were included 
in the present study. Mean (SD) for the age of the pal
tients with AA was 29.0 (15.5) years (n=53, range 13l
72 years with a median age of 22 years) while that of 
control subjects was 30.5 (15.3) years (n=32, range 14l
67 years with a median age of 25 years). The maleltolfel
male ratio of patients with AA was 3.1:1. There were 13 
patients (24.5%) with very severe aplastic anemia, 18 pal
tients (34%) with severe aplastic anemia and 22 patients 
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(41.5%) with nonlsevere aplastic anemia. The cause of 
AA was not obvious in 88.7% of the cases. A possible 
association of NSAIDs with the disease was found in 
11.3% cases. The most common clinical presentations 
were dyspnea on exertion, fatigue and pallor. There were 
no recurrent infections, but in 4 cases (7.5%) mouth ull
cer was present at diagnosis. Gum bleeding was present 
in 5 cases (9.4%).
Cell cycle analysis on the peripheral blood of patients 
with AA at the time of diagnosis showed that most of 
the cells were in G0/G1 phase (Table 1). The median 
Table 1. Cell cycle distribution of peripheral blood lymphocytes in control and aplastic 
anemia patients.
 Cell cycle phase Control(n=32)
Aplastic anemia
(n=53)
G0/G1 phase (%) 98.5 (0.33)  98.71 (1.09)
S phase (%) 0.89 (0.15) 0.87 (0.85)
G2/m phase (%) 0.58 (0.20) 0.42 (0.29)
Coefficient of variation (%) 3.24 (1.12) 3.47 (1.05)
 Data are mean and standard deviation.
Table 2. Relationship between the clinico-biological characteristics and S-phase 
fraction in aplastic anemia patients at diagnosis.
Characteristics SPF ≤0.59%(n=27)
SPF >0.59%
(n=26) P value
Hemoglobin (g/dl) 4.52 (1.91) 5.24 (1.82) NS
WBC count (×109/l) 2.46 (0.84) 2.78 (0.89) NS
platelet count (×109/l) 0.46 (0.22) 0.44 (0.20) NS
absolute neutrophil count 
(×109/l) 0.57 (0.53) 0.83 (0.60) NS
male, n (%)
Female, n (%)
21(77.8)
6 (22.2)
18 (69.2)
8 (30.8) NS
age 24.26 (11.8) 33.52 (17.5) .02
lactate dehydrogenase 
(iu/l) 323.4 (118.5) 439.9 (189.1) .01
Data are mean and standard deviation, unless noted otherwise.
Table 3. S-phase fraction (SpF) value and response to immunosuppressive therapy 
(cyclosporine) at 6 months.
SPF ≤0.59%
(n=27)
SPF >0.59%
(n=26)
Complete response, n (%) 1 (3.7) 3 (11.5)
partial response, n (%) 5 (18.6) 11 (42.3)
Overall response, n (%)* 6 (22.2) 14 (53.9)
Overall response: complete response + partial response *P=.018.
value of SPF in patients with AA was 0.59% with a 
range of 0.06% to 3.47%, which was lower than that of 
controls (median value 0.90%, range 0.54% to 1.16%). 
There were 8 patients who had an SPF value higher 
than the upper limit SPF value found in controls. In 
these patients, the mean SPF value was 2.69±0.75% 
with a range of 1.57% to 3.47%. On the basis of the mel
dian SPF, patients were divided into two groups whose 
clinical and hematological characteristics are shown in 
Table 2. Patients with SPF >0.59% had a higher mean 
age (P=.02) and serum lactate dehydrogenase (P=.01). 
than the patients with SPF≤0.59%. Patients with SPF 
>0.59% also had higher incidence of PNH (15.4% verl
sus 7.4% in the SPF ≤0.59% group). Chromosomal 
abnormalities in the form of trisomy 8 and trisomy 21 
were present in 2 patients (3.77%) with AA at the time 
of diagnosis. Both patients had SPF >0.59%. The mel
dian followlup of patients was 18 months (range, 6 to 24 
months). During the followlup, 3.7% and 11.5% patients 
developed dysplasia in the groups with SPF ≤0.59% and 
>0.59%, respectively. One patient with SPF >0.59% 
converted into AML. Half of the patients who had a 
higher SPF value than the upper limit SPF value of conl
trols at diagnosis developed dysplasia/AML during the 
followlup. Cytogenetic abnormalities developed during 
the followlup in five more cases. These abnormalities 
were trisomy 8 (two patients), trisomy 6 (two patients) 
and monosomy 7 (one patient). The incidence of cytogel
netic abnormalities was higher (19.2%) in patients with 
SPF >0.59% than in patients with SPF ≤0.59%. The 
patients with SPF >0.59% had a better response to iml
munosuppressive therapy (cyclosporine) that was statisl
tically significant (P=.018) (Table 3). Fourteen patients 
died during the study; most (64.3%) were in the SPF 
≤0.59% who also did not respond to therapy. 
DISCUSSIOn 
AA reflects the failure of proliferation of hematopoietic 
stem cells in bone marrow manifesting as a decrease in 
blood cell counts. The mechanisms suggested for bone 
marrow failure are: a) direct hematopoietic injury by 
chemicals, drugs or radiation to both proliferating and 
quiescent hematopoietic cells, and b) immunelmediated 
suppression of marrow cells.21 Therefore, patients with 
AA have very low proliferative rates, which rise from 
low to normal as patients respond to immunosuppresl
sive therapy. In a prospective, randomized, multicenter 
study of immunosuppressive therapy in patients with 
AA, a significantly higher overall response rate of 74% 
was found in ATG plus cyclosporine groups whereas the 
response to cyclosporine alone was 46% at 6 months.22 
However, the response to immunosuppressive therapy 
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in AA is quite variable (40% to 70%).23 The reason for 
this is not well known though it may depend on the age 
of patients, severity of the disease, presence of PNH 
and cytogenetic abnormalities.24l27 The occurrence 
of PNH in patients with AA is well known and may 
arise with disease progression. In various studies, 10% 
to 57% patients of AA developed a PNH clone during 
longlterm survival.28 The 10lyear cumulative incidence 
rate of MDS and AML in patients with AA respondl
ing to immunosuppressive therapy was 9.6% and 6.6%, 
respectively.29 It was not clear whether the transformal
tion was a natural course of the disease or due to iml
munosuppressive therapy. Furthermore, patients with 
AA having cytogenetic abnormalities are more prone 
to develop MDS and AML.17,18
It is likely that some patients diagnosed with AA 
actually have hypoplastic myelodysplastic syndrome 
(HMDS) that is not apparent enough to be diagnosed 
by current methods. Attempts have been made to asl
sess the proliferative behavior of hematopoietic cells 
in patients with AA to find evidence of dysplasia and 
thus to make a prognostic evaluation and therapeutic 
decisions. AA patients with dysplasia (HMDS) should 
be treated with BMT rather than immunosuppressive 
therapy.30 In recent years, hematologist and pathologists 
have widely applied immunohistochemistry techniques 
using antigens (proliferating cell nuclear antigen, CD34 
and p53) and mitotic activity on chromosome preparal
tions to assess the proliferative rate, but these are not 
reproducible and satisfactory.31l34 Flow cytometry meal
surement of cells in Slphase is a validated method for 
measuring cell proliferation. SPF has been studied in a 
number of hematological diseases and solid tumors for 
the purpose of classification, grading and prognosis.7l14 
Its advantage is that it can be used on a wide variety of 
tissue preparations, including peripheral blood, frozen 
biopsy specimens, fresh surgical samples and archival 
paraffin blocks. 
There are a few studies on the cell cycle and prolifl
erative behavior of cells in patients with AA, but none 
on SPF to our knowledge. We found that the SPF value 
in patients with AA was quite variable (range 0.06% to 
3.47%) and that the median value of SPF (0.59%) was 
lower than that in controls (median 0.90%, range 0.54% 
to 1.16%). This is conceivable since AA is characterized 
by limited proliferation of hematopoietic stem cells. In 
view of the wide variability in SPF in patients with AA, 
we classified patients into two groups based on the mel
dian value. Our data showed that the SPF rises with 
advanced age in patients with AA. Cytogenetic abnorl
malities were present in a higher proportion of patients 
with SPF >0.59% as compared to patients with SPF 
≤0.59%, which is supported by published reports that 
older AA patients are more likely to develop cytogel
netic abnormalities, dysplasia or AML.24 Although the 
majority of older patients, even those with SPF >0.59% 
did not show cytogenetic abnormalities, it is likely that 
they may be harboring dysplasia in the bone marrow 
that is not apparent morphologically. In such cases, 
SPF may be an indicator for evolving dysplasia in the 
bone marrow. 
We showed that during the followlup, 3.7% of pal
tients SPF ≤0.59% and 11.5% of patients with SPF 
>0.59% developed dysplasia. One patient converted 
into AML who belonged to SPF >0.59% whereas none 
of patients with SPF ≤0.59% converted into AML. We 
found that patients with a higher SPF value than the 
upper limit of SPF of controls at diagnosis were more 
prone to develop dysplasia/AML. This observation is in 
agreement with other reports on various hematological 
disorders as well as solid tumors.7l14 A serial measurel
ment of SPF in patients with AA may provide an early 
indication for development of dysplasia. The lower SPF 
value (≤0.59%) was associated with a poor response in 
our study. It is likely that patients with a lower SPF 
(≤0.59%) have a stem cell or precursor defect and thus 
show poor response. The proliferative deficit associated 
with poor response rate to immunosuppressive therapy 
indicates a more basic disorder of cell cycle regulation 
including increased rates of apoptosis or a greatly rel
duced stem cell pool. The initial difference in the prol
liferation rate as evident by SPF between patients with 
good treatment response and those with poor response 
may provide additional prognostic information and 
equally important, shed light on the pathogenetic hetl
erogeneity among patients with AA. 
In conclusion, SPF at the time of diagnosis may 
provide, independently of the peripheral blood count, 
information on the expected response to immunosupl
pressive therapy as well as propensity to evolve into 
MDS/AML. The assessment of the proliferative activl
ity by measuring SPF may add valuable information on 
the clinical course and may contribute to therapeutic 
decisions. 
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